Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lotte Group
Pharma
BeiGene, Legend, Eisai-Biogen—Fierce Pharma Asia
BeiGene's R&D head argues for TIGIT and PD-1. Legend scraps a CAR-T program. Eisai and Biogen's Aduhelm follow-up scores fast review.
Angus Liu
Jul 8, 2022 10:29am
Lotte is telegraphing plans to grow a former BMS plant
Jul 7, 2022 8:58am
MilliporeSigma to help Lotte stand up biologics production biz
Jul 1, 2022 10:01am
Hengrui, Merck-Kelun, Dr. Reddy's and more—Fierce Pharma Asia
May 20, 2022 9:15am
Lotte lays out $160M for a Bristol Myers biologics plant in NY
May 13, 2022 8:37am